Royalties. During the Royalty Period, AEON will be obligated to pay the Royalty to Medytox. Such Royalty payments will be made for a given Reporting Period within seventy-five (75) days of the end of each calendar quarter containing the applicable Reporting Period. Each Royalty payment shall be accompanied by a Sales and Royalty Report sent to Medytox at the E-mail address set forth in Section 13.4. For the avoidance of doubt, the Sales and Royalty Report shall be considered Confidential Information under this Agreement and shall be limited to those employees of Medytox that have a need to know such information for purposes of accounting for the Royalty and shall not be utilized for Medytox’s pricing strategy, sales, marketing, or other commercial activities.

Earned Royalties. During the applicable Royalty Term, Bausch Health shall make quarterly non-refundable, non-creditable (provided that specified costs incurred by Bausch Health pursuant to [Section 4.1(a)], [Section 4.3] or [Section 8.2(e)] may be credited against such payments, as described in [Section 4.1(a)], [Section 4.3] or [Section 8.2(e)], as the case may be) royalty payments to Clearside on Net Sales of all Products sold in the Original Territory or the Additional Regions, as applicable, during the applicable Calendar Quarter, as calculated by multiplying the applicable royalty rate set forth below by the corresponding amount of Net Sales of all such Products sold in the Original Territory or the Additional Regions, as applicable, for such Calendar Quarter. Notwithstanding the foregoing, no such royalties shall be due or payable by Bausch Health on the first Forty-Five Million Dollars ($45,000,000) of aggregate Net Sales of all Products in the Original Territory, calculated on a cumulative (and not annual) basis. Once cumulative Net Sales on all Products in the Original Territory achieves Forty-Five Million Dollars ($45,000,000), royalties will then be calculated as follows with respect to Net Sales of Products in the Original Territory: # on Net Sales of each XIPERE Product in the Original Territory, and the applicable royalty rates below for XIPERE Products will be applied, and # on Net Sales of each Other Product in the Original Territory, and the royalty rate below for Other Products will be applied.

Royalties. During the applicable Royalty Term and subject to Section 8.5, Kyorin will make non-refundable, non-creditable royalty payments to aTyr, on a Licensed Product-by-Licensed Product basis, based on aggregate Annual Net Sales of such Licensed Product in the Kyorin Territory by Kyorin and its Related Parties at the royalty rates set forth below:

Royalties. In further consideration of the licenses and other rights granted to Coya, subject to Section 5.5 (Royalty Adjustments) and [Section 5.6] (Sublicensing Income), on a country-by-country basis, Coya shall pay to ARScience Bio royalties in the amount of the marginal royalty rates set forth in the table below (“Royalty Rates”) based on the aggregate Net Sales resulting from the sale of all Products in the Territory during each Calendar Year of the applicable Royalty Term for each Product in each country (the “Annual Net Sales,” and such payments, “Royalties”).

Royalties. Beginning on the First Commercial Sale of any [[Organization A:Organization]] Licensed Product in a country, and ending upon expiration or termination of the Term, [[Organization A:Organization]] will pay [[Agenus:Organization]] a royalty on Net Sales of the Licensed Product by [[Organization A:Organization]] and its Affiliates in such country, calculated by multiplying the applicable royalty rate by the aggregate amount of Annual Net Sales of such Licensed Product in the Territory during the applicable calendar year (the “Royalty”):

Royalties. In consideration of Mosaic’s contributions to the Research and the licenses granted to Catalyst hereunder, beginning with the first commercial sale of Products in a country of the Territory by Catalyst, its Affiliates or Sublicensees, Catalyst shall pay Mosaic a running royalty of: ​.

Royalties. All royalties on sales theretofore made shall become immediately due and payable, provided, however, if this Agreement expires naturally in accordance with its terms, Licensee shall have the right to continue to make royalty payments pursuant to Article 9 hereof.

Royalties. Subject to Section 4.4, Earned Royalties will accrue on a Licensed Product-by-Licensed Product basis and country-by-country basis, for the duration of the Royalty Term and will be payable to Institute when Licensed Products are invoiced, or if not invoiced, when delivered or otherwise exploited by the Licensee, its Affiliate or Sublicensee in a manner constituting a Sale.

Earned Royalties. During the applicable Royalty Term, Bausch Health shall make quarterly non-refundable, non-creditable (provided that specified costs incurred by Bausch Health pursuant to [Section 4.1(a)], Section 4.3 or [Section 8.2(e)] may be credited against such payments, as described in [Section 4.1(a)], Section 4.3 or [Section 8.2(e)], as the case may be) royalty payments to Clearside on Net Sales of all Products sold in the Territory during the applicable Calendar Quarter, as calculated by multiplying the applicable royalty rate set forth below by the corresponding amount of Net Sales of all such Products sold in the Territory for such Calendar Quarter. Notwithstanding the foregoing, no such royalties shall be due or payable by Bausch Health on the first Thirty Million Dollars ($30,000,000) of aggregate Net Sales of all Products, calculated on a cumulative (and not annual) basis. Once cumulative Net Sales on all Products in the Territory achieves Thirty Million Dollars ($30,000,000), royalties will then be calculated as follows: # on Net Sales of each XIPERE Product, and the applicable royalty rates below for XIPERE Products will be applied, and # on Net Sales of each Other Product, and the royalty rate below for Other Products will be applied.

Royalties. For any Quarter in which Net Sales Per Unit of Customer Product (other than Customer Product sold under any COVAX Supply Agreement or GAVI Customer AP Agreement) exceed the Unit Threshold Price, Customer shall pay to Dynavax a royalty equal to ​ of the amount determined by multiplying # Adjusted Net Sales Per Unit in such Quarter, by # Units Sold in such Quarter. For clarity, no royalties shall be payable under this [Section 6.4] # for any portion of Net Sales Per Unit of Customer Product that does not exceed the Unit Threshold Price or # on any sales of Customer Product under any COVAX Supply Agreement or GAVI Customer AP Agreement.